<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03989531</url>
  </required_header>
  <id_info>
    <org_study_id>Accost</org_study_id>
    <nct_id>NCT03989531</nct_id>
  </id_info>
  <brief_title>Adrecizumab in Cardiogenic Shock</brief_title>
  <acronym>ACCOST-HH</acronym>
  <official_title>Investigator-initiated, Placebo-controlled, Double-blind, Multi-center, Randomized Trial to Assess the Efficacy and Safety of Adrecizumab in Subjects With Cardiogenic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. med. Mahir Karakas</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universit√§tsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiogenic shock is a serious medical condition with high mortality and morbidity. This&#xD;
      trial assesses safety, tolerability and efficacy of Adrecizumab on top of standard of care in&#xD;
      patients with cardiogenic shock.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Despite optimal treatment the mortality in patients with cardiogenic shock still exceeds 50%&#xD;
      and surviving patients mostly suffer from severe heart failure due to an impaired cardiac&#xD;
      function.It is hypothesized, that Adrenomedullin is a key player in the (dys)-regulation of&#xD;
      vascular integrity. Adrecizumab is the first-in-class humanized monoclonal&#xD;
      anti-Adrenomedullin antibody, and acts as a long-lasting plasma Adrenomedullin enhancer&#xD;
      stabilizing barrier function at a reasonable safety profile.When the anti-Adrenomedullin&#xD;
      antibody Adrecizumab is administered in the blood circulation at high concentrations by far&#xD;
      exceeding those of plasma Adrenomedullin, the compartmental distribution of Adrenomedullin is&#xD;
      altered. Adrecizumab, an IgG with a molecular weight of more than 150 kDa, is too large to&#xD;
      freely diffuse from the blood circulation to the interstitium. With its fast association&#xD;
      kinetics Adrecizumab quickly binds to Adrenomedullin in the blood circulation and &quot;pulls&quot;&#xD;
      Adrenomedullin, which has been initially located in the interstitium, from this compartment&#xD;
      to the blood circulation. The more Adrecizumab is applied, the stronger is the &quot;pulling&quot;&#xD;
      effect and the higher the resulting concentrations of Adrecizumab-bound Adrenomedullin in the&#xD;
      blood circulation. The increase of Adrecizumab-bound Adrenomedullin in the blood circulation&#xD;
      occurs within 5-15 minutes after administration of Adrecizumab, since it induces a&#xD;
      translocation of preformed Adrenomedullin. As a consequence of this redistribution, the&#xD;
      Adrenomedullin concentration in the interstitium decreases, and less Adrenomedullin is able&#xD;
      to act on smooth muscle cells to exert its vasodilatative activity. In the progression to&#xD;
      cardiogenic shock, when it comes to excessive vasodilation and hypotension, administration of&#xD;
      Adrecizumab thus can reduce vasodilation by substracting excessive levels of interstitially&#xD;
      located Adrenomedullin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 4, 2019</start_date>
  <completion_date type="Actual">April 26, 2021</completion_date>
  <primary_completion_date type="Actual">April 26, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Need of cardiovascular organ support within the first 30 days</measure>
    <time_frame>30 days</time_frame>
    <description>Number of days through day 30 without need for cardiovascular organ support, including vasopressors, or mechanical support (VA-ECMO, Impella)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day-Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Cardiogenic Shock</condition>
  <condition>Endothelial Dysfunction</condition>
  <arm_group>
    <arm_group_label>Adrecizumab on top of standard of care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 mg/kg body weight Adrecizumab diluted in up to 100 mL saline as single dose infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo on top of standard of care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>100 mL saline as single dose infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adrecizumab</intervention_name>
    <description>Drip infusion over 60 minutes</description>
    <arm_group_label>Adrecizumab on top of standard of care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Drip infusion over 60 minutes</description>
    <arm_group_label>Placebo on top of standard of care</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -Hospitalization for Cardiogenic shock (at the discretion of the local investigator)&#xD;
&#xD;
        Cardiogenic shock is usually defined as:&#xD;
&#xD;
          -  Systolic blood pressure &lt; 90 mmHg &gt; 30 min or inotropes required to maintain pressure&#xD;
             &gt; 90 mmHg during systole&#xD;
&#xD;
          -  Signs of left heart insufficiency and/ or pulmonary congestion&#xD;
&#xD;
          -  Signs of impaired organ perfusion with at least one of the following:&#xD;
&#xD;
          -  Altered mental status&#xD;
&#xD;
          -  Cold, clammy skin&#xD;
&#xD;
          -  Urine output &lt;30 ml/h&#xD;
&#xD;
          -  Serum lactate &gt;2mmol/l&#xD;
&#xD;
               -  Age above 18 years at time of screening&#xD;
&#xD;
               -  Body weight below 150 kg at time of screening&#xD;
&#xD;
               -  Females/Males who agree to comply with the applicable contraceptive requirements&#xD;
                  of the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cardiogenic shock due to significant arrhythmias, which include any of the following:&#xD;
             sustained ventricular tachycardia, bradycardia with sustained ventricular rate &lt;35&#xD;
             beats per minute, or atrial fibrillation/ flutter with sustained ventricular response&#xD;
             of &gt;160 beats per minute&#xD;
&#xD;
          -  Cardiogenic shock due to left ventricular outflow obstruction, obstructive&#xD;
             hypertrophic cardiomyopathy or severe aortic stenosis (i.e., aortic valve area &lt;0.8&#xD;
             cm2 or mean gradient &gt;50 mmHg on prior or current echocardiogram), and severe mitral&#xD;
             stenosis&#xD;
&#xD;
          -  Cardiogenic shock due to mechanical cause or severe bleeding&#xD;
&#xD;
          -  Cardiogenic shock due to untreated clinically significant CAD requiring&#xD;
             revascularization&#xD;
&#xD;
          -  Resuscitation &gt; 60 minutes&#xD;
&#xD;
          -  Severe pre-existing hepatic disease unrelated to cardiogenic shock&#xD;
&#xD;
          -  Severe pre-existing renal disease (dialysis) unrelated to cardiogenic shock etiology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahir Karakas, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Heart Center Hamburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Berlin, Campus Benjamin-Franklin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Heart Center Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2019</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universit√§tsklinikum Hamburg-Eppendorf</investigator_affiliation>
    <investigator_full_name>Dr. med. Mahir Karakas</investigator_full_name>
    <investigator_title>PD Dr Mahir Karakas, MBA</investigator_title>
  </responsible_party>
  <keyword>Cardiogenic Shock</keyword>
  <keyword>Adrecizumab</keyword>
  <keyword>Vascular integrity</keyword>
  <keyword>Endothelial dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

